5 questions facing pharma in 2024
Bio Pharma Dive
JANUARY 10, 2024
Many drugmakers hope to compete in obesity, while others seek to win oncology’s next era. In the background, a contentious drug pricing law looms.
Wed.Jan 10, 2024
306 
Vertex’s CASGEVY therapy gains approval in Saudi Arabia
Pharmaceutical Technology
JANUARY 10, 2024
Vertex Pharmaceuticals has announced the approval of CASGEVY (exagamglogene autotemcel [exa-cel]), the first CRISPR/Cas9 gene-edited therapy.
Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
A Crash Diet Could Be a Seriously Bad Idea For Weight Loss
AuroBlog - Aurous Healthcare Clinical Trials blog
JANUARY 10, 2024
Those trying to kick-start their weight loss or perhaps wanting to lose a few pounds before a big event or holiday may be tempted to try a crash diet.
JPM24: Novartis’ head start, FTC fallout and Bluebird’s price defense
Bio Pharma Dive
JANUARY 10, 2024
Radiopharma drugmakers spoke with BioPharma Dive about chasing Novartis in the hot field, while investors debated the impact of a surprise FTC challenge.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
January 10, 2024: In This Friday’s PCT Grand Rounds, a Lottery for Allocating Scarce COVID-19 Resources
Rethinking Clinical Trials
JANUARY 10, 2024
In this Friday's PCT Grand Rounds, Erin McCreary of the University of Pittsburgh will present "Design and Implementation of a Weighted Lottery to Equitably Allocate Scarce COVID-19 Resources." The Grand Rounds session will be held on Friday, January 12, 2024, at 1:00 pm eastern. McCreary is a clinical assistant professor of medicine at the University of Pittsburgh and the director of infectious diseases improvement and clinical research innovation at UPMC.
Biopharmaceutical drugs’ affordability driven by R&D cost and production complexity: Dr Tumbagi
AuroBlog - Aurous Healthcare Clinical Trials blog
JANUARY 10, 2024
Biopharmaceutical involves substantial investments in research, clinical trials, regulatory compliance, and manufacturing. Hence the affordability of these medicines are a complex issue, said Dr Amaresh Tumbagi, Karnataka additional drugs controller.
Sign up to get articles personalized to your interests!
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
More Trending
Novavax: Creating tomorrow’s vaccines today
pharmaphorum
JANUARY 10, 2024
Novavax is a leading pharmaceutical company dedicated to creating protein-based vaccines for diseases like COVID-19 and malaria. Learn more about their innovative vaccine development process and their commitment to creating a healthier future.
STADA and Alvotech’s win first EU-approval for Stelara biosimilar
Pharmaceutical Technology
JANUARY 10, 2024
STADA and Alvotech’s Uzpruvo gained an EU marketing authorisation, allowing it to be sold in the European Economic Area in 2024.
JPM24: Riding label expansions and launches, AZ plots course toward 'industry-leading growth' by 2030
Fierce Pharma
JANUARY 10, 2024
With a late-stage pipeline spanning more than 120 clinical trials and a firm grasp of five major disease areas, AstraZeneca appears confident heading into 2024. | In AZ's push to reach industry-leading growth by 2030, confidence is key, chief financial officer Aradhana Sarin said at the J.P. Morgan Healthcare Conference. Besides that goal, the company wants to be a top-3 player in its five disease areas of focus.
Alcon’s dry eye drug achieves primary endpoints in Phase III trials
Pharmaceutical Technology
JANUARY 10, 2024
Alcon plans to file for regulatory approval for its dry eye drug with the FDA in mid-2024 after Phase III studies met the primary endpoints.
Barinthus Bio announces $47m project to advance MERS coronavirus vaccine
Pharma Times
JANUARY 10, 2024
The partnership will advance VTP-500 from early development to phase 2 clinical trials
Precision BioSciences and TG Therapeutics sign azer-cel licence deal
Pharmaceutical Technology
JANUARY 10, 2024
Precision BioSciences and TG Therapeutics concluded a licensing agreement for developing azercabtagene-zapreleucel for autoimmune diseases.
JP Morgan Week 2024 - Day 2
pharmaphorum
JANUARY 10, 2024
On Day 2 of the JP Morgan 2024 conference, there are exciting presentations from companies such as Daiichi-Sankyo, Recode Therapeutics, and Vir Biotech. The focus was on innovative advancements in healthcare and the contributions of women in the industry. Learn more about the highlights of this day.
GSK acquires Aiolos Bio for $1.4bn to boost respiratory portfolio
Pharmaceutical Technology
JANUARY 10, 2024
GSK’s acquisition, which comes amid other big money moves in the pharma industry, aims to broaden its asthma drug range.
The New Age of Decentralized Clinical Trials
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Ensuring R&D investments deliver maximum potential: Notable ways to enhance clinical development strategy and design
pharmaphorum
JANUARY 10, 2024
Ensuring R&D investments deliver maximum potential: Notable ways to enhance clinical development strategy and design Mike.
Switching sales: Investigating the financial impacts of FDA’s priority vouchers
Pharmaceutical Technology
JANUARY 10, 2024
The second of a two part-series on priority review vouchers investigates trends in the vibrant market of million-dollar vouchers and how companies use them.
Life sciences real estate trends for 2024 and beyond
pharmaphorum
JANUARY 10, 2024
Explore the latest trends and projections in life sciences real estate, including the impact of digital health, the evolving needs of laboratory facilities, and the future of real estate in this sector. Stay ahead of the curve with insights into the industry's future.
BioArctic and Eisai’s Leqembi gains approval in China
Pharmaceutical Technology
JANUARY 10, 2024
BioArctic AB and Eisai have announced the approval of Leqembi in China for mild cognitive impairment associated with Alzheimer's disease.
Top 5 pharma marketing trends in 2024
pharmaphorum
JANUARY 10, 2024
Discover the top 5 pharma marketing trends to watch out for in 2024. From personalised marketing strategies to the power of video and omnichannel communication, explore how patient-centric approaches and generative AI are shaping the future of pharmaceutical marketing.
Venatorx and Menarini sign commercial deal for antibiotic
Pharmaceutical Technology
JANUARY 10, 2024
Venatorx and Menarini have signed an agreement for the commercialisation of the antibiotic cefepime-taniborbactam, in 96 countries.
AbbVie launches pump-based Parkinson’s drug in EU
pharmaphorum
JANUARY 10, 2024
AbbVie has launched its Produodopa therapy for Parkinson’s disease onto the market in the EU, becoming the first and only 24-hour subcutaneous infusion therapy for the neurodegenerative disorder.
JPM24: After 'clearing the decks,' Alkermes ready to roll as pure-play neuroscience company
Fierce Pharma
JANUARY 10, 2024
Age 37 might be old for a “coming-out party,” but that’s the situation for Alkermes at this year’s J.P. Morgan Healthcare Conference, chief operating officer Blair Jackson said in an interview. | Age 37 might be old for a “coming-out party,” but that’s the situation for Alkermes at this year’s J.P. Morgan Healthcare Conference, said chief operating officer Blair Jackson.
The New Age of Decentralized Clinical Trials
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
JPM: Precision Bio continues offload of CAR-T rights
pharmaphorum
JANUARY 10, 2024
Precision BioSciences licenses non-cancer uses of its allogeneic CAR-T therapy azer-cel to TG Therapeutics as it pivots to in vivo applications of its gene-editing technology
JPM24: BioMarin's new CEO Hardy says top priority is expansion of dwarfism drug Voxzogo
Fierce Pharma
JANUARY 10, 2024
In his first presentation as the new CEO of BioMarin, Alexander Hardy left no doubt about his mission for the rare and genetic disease specialist. | In his first presentation as the new CEO of BioMarin, Alexander Hardy left no doubt about his mission for the rare and genetic disease specialist. The top priority for the former Genentech CEO is to accelerate and maximize the commercial potential of dwarfism drug Voxzogo.
Patient Perspectives: After a lung cancer diagnosis, turning to art and medical research
Antidote
JANUARY 10, 2024
One of the most important results of the work we do at Antidote is directly impacting the lives of patients — and getting to hear their stories is a constant reminder of why we do what we do.
JPM24: Bluebird CEO points to 'very innovative contract' to defend Lyfgenia's pricing premium over CRISPR rival
Fierce Pharma
JANUARY 10, 2024
San Francisco—Bluebird bio’s 40% list-price | Bluebird bio’s 40% list-price premium for Lyfgenia compared with Vertex and CRISPR Therapeutics’ sickle cell disease drug surprised many industry watchers last month. But bluebird CEO Andrew Obenshain argues the prices for the gene therapy rivals shouldn’t be compared directly.
Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Alphabet spinout SandboxAQ buys Good Chemistry
pharmaphorum
JANUARY 10, 2024
Quantum computing and artificial intelligence specialist SandboxAQ has bought Good Chemistry in a deal focused on drug discovery and material science
JPM24: In booming obesity field, Novo Nordisk is 'just getting going,' CEO says
Fierce Pharma
JANUARY 10, 2024
Despite persistent supply hitches since Wegovy’s launch in 2021, Novo Nordisk has quickly garnered blockbuster sales in the newly untapped obesity market. | Despite persistent supply hitches since Wegovy’s launch in 2021, Novo Nordisk has quickly garnered blockbuster sales in the newly untapped obesity market. And to hear Novo’s CEO Lars Fruergaard Jørgensen tell it, the company is "just getting going" in the field.
UK study backs whole-genome screening for cancer care
pharmaphorum
JANUARY 10, 2024
UK study led by Genomics England drawing on 100,000 Genomes Project and real-world clinical data backs use of whole-genome sequencing in cancer care
Evotec to advance drug discovery in collaboration with the Crohn’s & Colitis Foundation
Outsourcing Pharma
JANUARY 10, 2024
Evotecâs end-to-end integrated research and development platform will be able to advance drug discovery for two drug targets which is why it has joined forces with the Crohnâs & Colitis Foundation.
How Machine Learning Drives Clinical Trial Efficiency
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Let's personalize your content